Abstract: A topical skin ointment for application onto the skin of individuals suffering from minor skin irritations such as dry chapped skin, minor cuts, and scrapes and abrasions. The topical skin ointment includes ingredients to reduce the discomfort associated with these types of skin irritations as well ingredients to promote the natural healing process.

Abstract: The invention relates to a transparent or translucent cosmetic emulsion comprising an aqueous phase, a fatty phase and a surfactant, the said fatty phase containing a miscible mixture of at least one cosmetic oil and of at least one volatile fluoro compound, the latter compound being present in a proportion such that the refractive index of the fatty phase is equal to ±0.05 of that of the aqueous phase. The invention also relates to the process for preparing the emulsion. Use of the emulsion in skincare, hair conditioning and antisun protection and/or artificial tanning.

Abstract: The invention relates to cosmetic and pharmaceutical creams in the form of an oil-in-water emulsion containing at least one polar oil as the oil component, said polar oil having an interfacial tension (&ggr;1) with water of less than 30 mN/m at 25° C., and at least one plant protein as the emulsifier, a 1 wt % aqueous solution of said plant protein having an interfacial tension (&ggr;2) with the oil component at 25° C. which is less than the interfacial tension &ggr;1 between oil and water. Protein or protein-containing meals consisting of oats, wheat or peas are preferred as emulsifiers, whilst the oil components preferably belong to the group of C8-C22 fatty acid esters of monovalent or polyvalent C2-C22 alkanol esters of monovalent or polyvalent C2-C6 hydroxycarboxylic acids.

Abstract: The invention relates to a cosmetic composition for protecting the skin against ultraviolet radiation of wavelengths between 280 and 400 nm, comprising, in a cosmetic vehicle containing at least one fatty phase, an effective amount of copper (II) bis(3,5-diisopropylsalicylate). The composition can contain, in addition, one or more UV-B and/or UV/A sunscreens.

Abstract: The invention provides a tablet and methods for making the tablet comprising a gel-forming material and at least one particle comprising an active agent in contact with a coating material to modify release of the active agent.

Abstract: A composition for topical use, comprising an oil-in-water emulsion formed from lipid vesicles consisting of oily globules, each having a lamellar liquid crystal coating obtained from at least one surfactant, dispersed in an aqueous phase containing at least one hydrophilic acidic active agent but which does not contain a gelling agent.

Abstract: The present invention is a method and composition to increase bone strength in a manner that decreases fracture incidence, which may or may not include increasing bone mineral density (“BMD”). The invention includes administering an effective amount of a bisphosphonate to a host in need thereof to increase bone strength, which inhibits the apoptosis of osteoblasts and osteocytes, without a significant effect on osteoclasts. In one embodiment, the bisphosphonate is not 1-amino-3-(N,N-dimethylamino)-propyliden-1,1-bisphosphonic acid or its pharmaceutically acceptable salt. An increase in osteoblast life span can lead to an increase in bone mass, i.e., an anabolic effect. Preservation of osteocyte life span can increase bone strength, which may be disproportional to the increase in bone mass.

Abstract: The invention relates to novel indanylidene compounds which are effective in absorbing ultra violet radiation and to light screening compositions including the indanylidene compounds of the general formula I wherein X is O or NH; R1 is a C1-C20 alkyl, C2-C20 alkyl in which at least one methylene group is replaced by oxygen, C3-C20 alkenyl, C3-C20 alkynyl or a group YS; R2 is a C1-C20 alkyl, C2-C20 alkyl in which at least one methylene group is replaced by oxygen, C3-C20 alkenyl, C3-C20 alkynyl or a group YS; or R1 and R2 may combine on adjacent C-atoms to form a dioxomethylene ring; R3 is a C1-C20 alkyl, C2-C20 alkyl in which at least one methylene group is replaced by oxygen, C3-C20 alkenyl, C3-C20 alkynyl or a group YS; R4, R5, R6 are each independently H or C1-C20 alkyl; n is 0, 1 or 2; Y is a linker group; S is a silane-, an oligosiloxane- or a polysiloxane-moiety; with the proviso that at least one of the R1, R2or R3 residues is YS.

Abstract: The invention relates to novel aminouracils of the general formula (I) in which, Q, R1, R2, R3, R4, R5, R6 and R7 are each as defined in the description, to their use as herbicides and to novel intermediates.

Abstract: An emulsion slurry for cosmetic products, which comprises particles of pigments d/or extender pigments having a lipophilic moiety attached to the surface thereof and cosmetically acceptable oil component or oily material or combination of both dispersed in a liquid suspending medium comprising a mixture of water and oil.

Abstract: The invention relates to an alimentary integrator constitued by a compound of potassium bicarbonate (KHCO3) and an anti-oxidant agent that comprises D ribose (C6H10O5) and that can comprise ascorbic acid L (C6H8O6).

Abstract: A liquid composition applied transdermally for relief of pain comprising alcohol in an amount by weight of about 57 to about 91 percent; glycerin in an amount by weight of about 1 to about 12 percent; an analgesic agent in an amount by weight of about 2 to about 28 percent, the analgesic agent comprising a derivative of salicylic acid; methylsulfonylmethane in an amount by weight of about 0.02 to 5 percent; and emu oil in an amount by weight of about 0.01 to 3 percent, the liquid composition permeating skin to relieve pain. The composition further comprising, as an additional feature, aloe vera in an amount by weight of at least about 0.05 percent and having an amount by weight of about 0.05 to 4 percent. The composition features transdermal pain relief such that a patient can apply the analgesic agent directly to an area of pain without such side effects as stomach irritation which is normally associated with aspirin. The composition may be sprayed or rolled directly onto the painful area.

Abstract: The invention is directed to novel tablets comprising isoflavone-containing plant extract and water-insoluble polysaccharides, and methods of manufacturing them.

Abstract: This invention is directed to an oral solid, rapidly disintegrating, freeze-dried dosage form containing coarse particles of a pharmaceutically active material which are uncoated or coated with a polymer or lipid material. Preferably, the oral dosage form comprises coarse particles having a size in the range of 50 micron to 400 micron. The oral solid rapidly disintegrating dosage form according to the present invention preferably disintegrates in the oral cavity in less than 10 seconds.

Abstract: A colonic drug delivery composition contains a first polysaccharide and a second polysaccharide wherein both polysaccharide are degradable by colonic enzymes and are mixed at a environmental pH of about 7 or above, without use of a cross-linking agent. A colon selective pharmaceutical composition and dosage form for oral delivery of a drug, diagnostic reagent, or mixture thereof includes the drug, diagnostic reagent, or mixture thereof in contact with the polysaccharide composition. A method of preparing such a colonic drug delivery composition and the colon selective pharmaceutical composition and dosage from are also disclosed.

Abstract: The present invention relates to a liquid, substantially anhydrous eutectic mixture comprising a principal acid component, such as a hydroxy acid, and at least one other component selected from the group consisting of a carbohydrate, a polyol, an amino acid, and a carboxylic acid. The mixtures remain liquid at room temperature, are relatively non-irritating, and can be used to deliver higher levels of the principal acid than would ordinarily be possible. The invention also provides a method of making such a mixture comprising heating the component having the lowest melting point to the temperature at which it melts, dissolving the remaining component or components in the melted component, and allowing the mixture to cool.

Abstract: The invention is a fibrin glue that avoids the use-of fibrinogenand thus eliminates the need for premixing and premature clot formation. The fibrin glue of the invention comprises thrombin, thromboplastin and calcium and may have clotting Factors, VII, IX and X, and the like. The invention also comprises a biosealant for use with the fibrin glue without fibrinogen or for use alone. The biosealant is a two component mixture of gelatin/resorcinol and. glyoxal/glutaraldehyde/4-(p-maleimidophenyl) butyric acid. The two components are mixed on use.

Abstract: A flavonoid-containing sunscreen composition having UV absorbency at 282 nm in water contains at least one flavanone and at least one flavone, the flavanone providing 75 to 98% of the UV absorbency at 282 nm and the flavone providing 2 to 25% of the absorbency at 282 nm. The composition is formed of flavonoids extracted from citrus fruit using water, and separating the extracted flavonoids using a sorbent material, and then recovering the flavonoids from the sorbent material using a solvent.

Abstract: The present invention relates to a cosmetic stick composition comprising (a) a skin care agent and (b) a solid wax, wherein the composition comprises less than 1%, by weight, of oil, and methods of using such composition.

Abstract: The present invention relates to the use of pantothenic acid and/or its derivatives for treating dermatological disorders which involve mastocyte degranulation, such as atopic dermatitis, psoriasis, contact eczema, skin allergies, skin inflammation due to insect bites, skin allergies, senile pruritus, and to compositions comprising pantothenic acid and/or its derivatives, glycine and pharmaceutically and/or cosmetically acceptable additives which compositions are synergistic for the inhibition of mastocyte degranulation.